Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 26

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Unusual resistance patterns in macrolide-resistant Streptococcus pyogenes harbouring erm(A)

Malhotra-Kumar, Surbhi, Mazzariol, Annarita, Van Heirstraeten, Liesbet, Lammens, Christine, de Rijk, Peter, Cornaglia, Giuseppe, Goossens, Herman · 2009 · Journal of Antimicrobial Chemotherapy

Abstract

BACKGROUND: We identified erm(A)-harbouring Streptococcus pyogenes that expressed three variant phenotypes: (1) low-level resistance to erythromycin (MICs 1-4 mg/L) but high azithromycin MICs in absolute terms (16-64 mg/L; n=6); (2) same as (1) but with a high clindamycin MIC (256 mg/L; n=1); and (3) high-level constitutive MLS (cMLS) resistance (n=1). Here we analysed the genetic basis of these novel phenotypes. METHODS: The presence of erm(A) and the absence of macrolide/lincosamide resistance genes erm(B), mef and cfr were confirmed by PCR. erm(A), 23S rRNA, L4 and L22 genes were sequenced. Mutant erm(A) genes were cloned and electrotransformed into the macrolide-susceptible Escherichia coli AG100A. Clonality was determined by emm typing and PFGE. Effects of the identified mutations on free energy changes (DeltaG) and putative configurations of the leader sequence were studied in silico. RESULTS: Point mutations (G98A, A137C, C140T and G205A) were observed in the erm(A) regulatory region of all eight erm(A)-harbouring S. pyogenes. Five and two isolates belonged to emm77 and emm89 clones, respectively, and one isolate was an emm1. E. coli transformed with mutant erm(A) harbouring G98A, A137C or C140T mutations (phenotypes 1 and 2) did not express high-level azithromycin or clindamycin resistance. However, cMLS resistance was clearly observed in transformants with erm(A) harbouring both A137C and G205A mutations (phenotype 3). In silico analysis showed that DeltaG was minor except for the G205A mutation. Secondary structure predictions further showed that the A137C and G205A mutations together abolished the hairpin sequestering the ribosome-binding and initiation sites of the erm(A) gene, explaining the cMLS phenotype 3. CONCLUSIONS: We report point mutations in the erm(A) regulatory region leading to constitutive methylase expression and the presence of additional, as yet unidentified mechanisms mediating high-level azithromycin and clindamycin resistance in erm(A)-harbouring S. pyogenes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkn432

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. Malhotra-Kumar, 2005, Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–2003, Emerg Infect Dis, 11, 939, 10.3201/eid1106.041247 · doi:10.3201/eid1106.041247
  2. Malhotra-Kumar, 2007, Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci among healthy volunteers: a randomised, double-blind, placebo-controlled study, Lancet, 369, 482, 10.1016/S0140-6736(07)60235-9 · DOI · Paper page
  3. Weisblum, 1995, Insights into erythromycin action from studies of its activity as inducer of resistance, Antimicrob Agents Chemother, 39, 797, 10.1128/AAC.39.4.797 · DOI · Paper page
  4. Fines, 2001, In vitro selection of resistance to clindamycin related to alterations in the attenuator of the erm(TR) gene of Streptococcus pyogenes UCN1 inducibly resistant to erythromycin, J Antimicrob Chemother, 48, 411, 10.1093/jac/48.3.411 · doi:10.1093/jac/48.3.411
  5. Doktor, 2005, Differences in the DNA sequences in the upstream attenuator region of erm(A) in clinical isolates of Streptococcus pyogenes and their correlation with macrolide/lincosamide resistance, Antimicrob Agents Chemother, 49, 3070, 10.1128/AAC.49.7.3070-3072.2005 · doi:10.1128/aac.49.7.3070-3072.2005
  6. Mayford, 1990, The ermC leader peptide: amino acid alterations leading to differential efficiency of induction by macrolide–lincosamide–streptogramin B antibiotics, J Bacteriol, 172, 3772, 10.1128/jb.172.7.3772-3779.1990 · DOI
  7. Clinical and Laboratory Standards Institute, 2006, Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement M100-S16
  8. Malhotra-Kumar, 2005, Multiplex PCR for simultaneous detection of macrolide and tetracycline resistance determinants in streptococci, Antimicrob Agents Chemother, 49, 4798, 10.1128/AAC.49.11.4798-4800.2005 · DOI · Paper page
  9. Malhotra-Kumar, 2003, Bacitracin-resistant clone of Streptococcus pyogenes isolated from pharyngitis patients in Belgium, J Clin Microbiol, 41, 5282, 10.1128/JCM.41.11.5282-5284.2003 · DOI
  10. Malbruny, 2002, Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations, J Antimicrob Chemother, 49, 935, 10.1093/jac/dkf038 · doi:10.1093/jac/dkf038
  11. De Rijk, 1993, DCSE, an interactive tool for sequence alignment and secondary structure research, Comput Appl Biosci, 9, 735
  12. Zuker, 2003, Mfold web server for nucleic acid folding and hybridization prediction, Nucleic Acids Res, 31, 3406, 10.1093/nar/gkg595 · DOI · Paper page
  13. De Rijk, 2003, RnaViz 2: an improved representation of RNA secondary structure, Bioinformatics, 19, 299, 10.1093/bioinformatics/19.2.299 · doi:10.1093/bioinformatics/19.2.299
  14. Horinouchi, 1981, The control region for erythromycin resistance: free energy changes related to induction and mutation to constitutive expression, Mol Gen Genet, 182, 341, 10.1007/BF00269681 · doi:10.1007/bf00269681

Cited by

See all 26

Metadata

Authors
Malhotra-Kumar, S., Mazzariol, A., Van Heirstraeten, L., Lammens, C., de Rijk, P., Cornaglia, G., & Goossens, H.
Venue
Journal of Antimicrobial Chemotherapy
Published
2008-10-24
Volume
63
Issue
1
Pages
42-46
ISSN
  • 1460-2091
  • 0305-7453
Cited by
26
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.